

# Is the pulsed dye laser an effective adjuvant to topical therapy for psoriatic plaques?

<b>Submission date</b> 29/09/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 29/09/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 13/12/2013	<b>Condition category</b> Skin and Connective Tissue Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Emily McGrath

**Contact details**  
Royal Devon & Exeter Hospital (Wonford)  
Barrack Road  
Exeter  
United Kingdom  
EX2 5DW  
+44 (0)1392 402250

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

**Secondary identifying numbers**  
N0203173357

## Study information

## Scientific Title

### Study objectives

Pulsed dye laser treatments when used three times over three months with standard topical therapy effectively prevents recurrence of psoriatic plaques when compared to standard topical therapy alone.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Not specified

### Study type(s)

Treatment

### Participant information sheet

### Health condition(s) or problem(s) studied

Psoriasis

### Interventions

Aim to recruit 20 patients. Informed consent will be obtained. Two symmetrical, similar plaques will be selected by the investigator and randomly allocated to either topical therapy alone, or topical therapy and the pulsed dye laser treatment. The lesions will be photographed, measured and scored according to the validated Psoriasis Area Severity Index (PASI). Both plaques will be treated with Dovobet ointment twice daily for four weeks, after which the plaque allocated to laser treatment would be treated with a short pulse width (500 microseconds) pulsed dye laser once monthly for three months, in addition to standard topical therapy (Dovonex ointment twice daily). The control plaques would be treated with standard topical therapy throughout. At the end of the treatment period, plaques would be examined by an investigator blinded to the treatment groups. The skin would be photographed and any residual lesion measured and scored according to the modified PASI score by an assessor blinded to the treatment groups.

### Intervention Type

Other

### Phase

Not Specified

**Primary outcome measure**

Pulsed dye laser treatments when used three times over three months with standard topical therapy effectively prevents recurrence of psoriatic plaques when compared to standard topical therapy alone.

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

14/09/2005

**Completion date**

14/06/2007

## Eligibility

**Key inclusion criteria**

20 patients with chronic plaque psoriasis, who are on topical treatment only and have symmetrical plaques on legs between 2 and 5 cm in diameter.

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

20

**Key exclusion criteria**

1. Patients under 18 or over 80 years of age
2. Patients who have had systemic or ultraviolet light therapy within past 4 weeks
3. Patients who are unable to attend the laser unit on the six occasions needed

**Date of first enrolment**

14/09/2005

**Date of final enrolment**

14/06/2007

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**  
**Royal Devon & Exeter Hospital (Wonford)**  
Exeter  
United Kingdom  
EX2 5DW

## Sponsor information

### Organisation

Record Provided by the NHSTCT Register - 2006 Update - Department of Health

### Sponsor details

The Department of Health, Richmond House, 79 Whitehall  
London  
United Kingdom  
SW1A 2NL  
+44 (0)20 7307 2622  
dhmail@doh.gsi.org.uk

### Sponsor type

Government

### Website

<http://www.dh.gov.uk/Home/fs/en>

## Funder(s)

### Funder type

Government

### Funder Name

Royal Devon and Exeter NHS Trust

### Funder Name

NHS R&D Support Funding

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration